Organisation paid for research Program year 2025 Source: CMS Open Payments

Dana Farber Partners Cancercare Inc

Neither a doctor nor a teaching hospital

Research payments

$23,685,893

508 payments

Through program year 2025, Dana Farber Partners Cancercare Inc is reported as receiving $23,685,893 in research payments, across 508 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,914,191	22
2024	Research	$2,099,295	32
2023	Research	$4,167,029	59
2022	Research	$5,059,596	109
2021	Research	$5,126,904	128
2020	Research	$2,381,259	85
2019	Research	$2,937,620	73

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $19,211,482 153 payments
Janssen Research & Development, LLC $1,899,467 316 payments
Regeneron Pharmaceuticals, Inc. $1,264,963 13 payments
Merck Sharp & Dohme Corporation $894,159 9 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $176,680 3 payments
Otsuka Pharmaceutical Co., Ltd. $155,615 8 payments
Takeda Pharmaceuticals U.S.A., Inc. $67,529 5 payments
Omeros Corporation $16,000 1 payment

Studies the money was for Research payments · program years 2019–2025

0000000000000000000000000000000000000000000000000000000000000000214440 $6,474,467 30 payments
214440 $4,887,469 19 payments
Study name not reported $2,519,095 16 payments
214381 $1,790,921 16 payments
0000000000000000000000000000000000000000000000000000000000000000214381 $1,616,587 15 payments
0000000000000000000000000000000000000000000000000000000000000000214376 $1,236,349 11 payments
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20 B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy $739,527 6 payments
214376 $505,622 7 payments
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy $446,779 6 payments
A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non Small Cell Lung Cancer $367,484 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.